Work

Avelumab flat dose regimen: Justification for use in advanced renal cell carcinoma (aRCC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.5_suppl.32

Authors: John B. A. G. Haanen, Joanna C. Masters, Bo Huang, Toni K. Choueiri, Robert J. Motzer, Akash Khandelwal, Haiqing (Isaac) Dai, Alessandra di Pietro, Satjit Brar, Brian I. Rini, Laurence Albiges, James M. G. Larkin

Institutions: The Netherlands Cancer Institute, Pfizer (United States), Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Memorial Sloan Kettering Cancer Center, Merck KGaA, Darmstadt (Germany), Cleveland Clinic, Institut Gustave Roussy, Royal Marsden NHS Foundation Trust

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3004890286

Cites:

Cited by:

Related to: 10